Hangzhou Tigermed Consulting Co., Ltd. Class H (3347) AI Stock Analysis

• Market Cap: €47.62B
• Dividend Yield: 0.69%
• Average Volume (3M): 5.03M
• Price to Earnings (P/E): 104.3
• Beta (1Y): 1.92
• Revenue Growth: -11.12%
• EPS Growth: -80.33%
• Country: HK
• Employees: 10,185
• Sector: Healthcare
• Sector Strength: 39
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 0.20
• Shares Outstanding: 123,124,800
• 10 Day Avg. Volume: 3,655,358
• 30 Day Avg. Volume: 5,034,440
• PEG Ratio: -1.15
• Price to Book (P/B): 3.52
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 75.77
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €34.19
• Price Target Upside: -29.06% Downside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

• Rating: 65 Neutral
• Price Target: ―

Hangzhou Tigermed Consulting Co., Ltd. Class H receives a score of 65, reflecting its strong financial performance in terms of operational margins and balance sheet stability. However, the decline in revenue and cash flow, coupled with weak technical indicators and a high P/E ratio, suggest challenges in maintaining current valuation levels. Improving revenue growth and cash flow will be essential for enhancing future prospects.

Hangzhou Tigermed Consulting Co., Ltd. Class H Business Overview & Revenue Model

Company Description

Hangzhou Tigermed Consulting Co., Ltd. provides contract research organization services in the People's Republic of China and internationally. It operates in Clinical Trial Solutions, and Clinical-related and Laboratory Services segments. The company offers regulatory submission and approval, medical translation, and good manufacturing practice (GMP) consulting services; and clinical services in the areas of medical science, early clinical and late phase development, medical monitoring, project management, patient recruitment, and quality management system. It also provides biometrics services comprising data management, biostatistics, and statistical programming; and integrated technology services, such as site management, pharmacovigilance, third party audit and training, medical imaging, clinical trial system solution, central laboratory, pre-clinical, and research hospital. Further, the company offers medical device/ in vitro diagnostics (IVD) services comprising medical device testing, regulatory submission, clinical evaluation and trials, GMP certificate, EU MDR and IVDR preparation, and value-added services; and post-marketing study, real world evidence, and vaccine clinical trial services. Hangzhou Tigermed Consulting Co., Ltd. was incorporated in 2004 and is headquartered in Hangzhou, the People's Republic of China.

How the Company Makes Money

Hangzhou Tigermed Consulting Co., Ltd. generates revenue primarily through its suite of clinical trial services offered to pharmaceutical and biotechnology companies. The company charges fees for its end-to-end service offerings, including clinical trial management, project management, and consulting. Key revenue streams include contracts for conducting clinical trials, data management services, and regulatory consulting. Tigermed's earnings are bolstered by long-term partnerships with global pharmaceutical giants, ongoing demand for clinical research outsourcing, and its ability to provide high-quality, efficient, and compliant solutions that accelerate the drug development process.

Hangzhou Tigermed Consulting Co., Ltd. Class H Financial Statement Overview

Summary

Hangzhou Tigermed Consulting Co., Ltd. Class H demonstrates strong operational margins and a solid balance sheet, highlighting financial prudence. However, declining revenues and net income in the TTM, coupled with reduced operating cash flow, pose challenges for future growth and liquidity. Strengthening revenue generation and cash flow will be critical for sustaining financial health.

Income Statement

The company's gross profit margin and EBIT margin are strong, indicating efficient cost management and operational performance. However, revenue and net income have declined in the TTM, showing a negative growth trend. Despite this, the company maintains a healthy EBITDA margin, suggesting resilience in operational profitability.

Balance Sheet

The debt-to-equity ratio is low, indicating prudent financial leverage. The equity ratio is high, reflecting financial stability and strong asset backing. Return on equity has declined, suggesting a need for improved profitability to enhance shareholder returns.

Cash Flow

Operating cash flow has decreased significantly in the TTM, raising concerns about cash generation from core operations. The free cash flow to net income ratio is positive, but lower operating cash flow may impact future liquidity. The company has maintained positive free cash flow, albeit at a reduced level.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	6.51B	6.60B	7.38B	7.09B	5.21B	3.19B
Gross Profit	2.08B	2.24B	2.85B	2.81B	2.27B	1.51B
EBITDA	933.06M	1.13B	2.91B	2.42B	2.11B	1.27B
Net Income	743.83M	405.14M	2.02B	2.01B	2.87B	1.75B
Balance Sheet
Total Assets	28.73B	28.67B	29.68B	27.45B	23.74B	19.51B
Cash, Cash Equivalents and Short-Term Investments	1.68B	2.13B	7.46B	7.88B	8.57B	10.15B
Total Debt	2.85B	2.63B	2.83B	2.80B	1.19B	384.94M
Total Liabilities	4.82B	4.61B	5.23B	4.77B	3.14B	1.65B
Stockholders Equity	20.53B	20.67B	21.03B	19.58B	18.12B	16.12B
Cash Flow
Free Cash Flow	589.58M	740.45M	836.68M	908.90M	1.06B	842.18M
Operating Cash Flow	33.12M	1.10B	1.15B	1.36B	1.42B	998.68M
Investing Cash Flow	983.99M	―	-1.53B	―	―	―
Financing Cash Flow	203.79M	―	-7.81M	809.25M	―	9.34B

Hangzhou Tigermed Consulting Co., Ltd. Class H Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 48.20
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:3347, the sentiment is Positive. The current price of 48.2 is above the 20-day moving average (MA) of 39.50, above the 50-day MA of 33.63, and above the 200-day MA of 33.01, indicating a bullish trend. The MACD of 2.87 indicates Negative momentum. The RSI at 76.79 is Negative, neither overbought nor oversold. The STOCH value of 92.87 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:3347.

Hangzhou Tigermed Consulting Co., Ltd. Class H Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
3347	65 Neutral	€47.62B	104.27	1.58%	0.69%	-11.12%	-80.33%
Sector *	52 Neutral	$7.53B	0.20	-61.87%	2.28%	16.72%	1.10%
17Q1		€4.90B	13.61	14.15%	1.28%	―	―
2276	75 Outperform	HK$19.15B	37.39	28.81%	0.88%	14.99%	31.70%
6821	69 Neutral	HK$33.06B	26.02	5.72%	1.53%	-15.81%	-48.17%
2367	64 Neutral	HK$61.13B	26.02	36.16%	1.11%	54.44%	35.90%

Hangzhou Tigermed Consulting Co., Ltd. Class H Corporate Events

Hangzhou Tigermed Updates 2024 Final Dividend Details

Hangzhou Tigermed Consulting Co., Ltd. announced an update regarding its final cash dividend for the year ended December 31, 2024. The dividend, set at RMB 3 per 10 shares, will be paid on July 31, 2025, following shareholder approval on May 30, 2025. The announcement includes details on the withholding tax rates applicable to different categories of shareholders, with non-resident enterprises and individuals subject to a 10% tax and mainland individual investors facing a 20% tax. This update clarifies the default currency for dividend payment and emphasizes the company’s commitment to transparent financial practices, potentially impacting investor relations and market perception.

Hangzhou Tigermed Consulting Announces 2024 AGM Agenda

Hangzhou Tigermed Consulting Co., Ltd. has announced the schedule for its 2024 Annual General Meeting, which will take place on May 30, 2025. The meeting will address several key resolutions, including the approval of the 2024 Annual Report, financial statements, profit distribution plan, and the appointment of an auditor for 2025. Additionally, the meeting will consider changes in the use of proceeds from the H Shares offering, remuneration standards for directors and supervisors, and amendments to the Articles of Association. These resolutions are pivotal for the company’s strategic direction and governance, potentially impacting its financial management and shareholder relations.

Hangzhou Tigermed to Hold 2025 H Share Class Meeting for Share Repurchase Mandate

Hangzhou Tigermed Consulting Co., Ltd. has announced the 2025 First H Share Class Meeting, scheduled for May 30, 2025, in Hangzhou, China. The meeting will consider a special resolution to grant the Board a general mandate to repurchase H Shares, which could impact the company’s share structure and market positioning.

Hangzhou Tigermed Releases 2025 Q1 Report

Hangzhou Tigermed Consulting Co., Ltd. released its first quarterly report for 2025, highlighting that the financial statements were prepared according to the China Accounting Standards for Business Enterprises and remain unaudited. The report serves as a disclosure in compliance with Hong Kong’s listing rules, providing stakeholders with essential financial information.

Hangzhou Tigermed Consulting Announces Board Meeting for Quarterly Report Review

Hangzhou Tigermed Consulting Co., Ltd. has announced that its board of directors will meet on April 28, 2025, to review and approve the company’s first quarterly report for the period ending March 31, 2025. This meeting is significant as it will provide insights into the company’s financial performance and strategic direction, potentially impacting its market positioning and stakeholder interests.

Hangzhou Tigermed Announces Strategic Reallocation of H Shares Proceeds

Hangzhou Tigermed Consulting Co., Ltd. announced a further change in the use of proceeds from its H Shares Offering in 2025, with a focus on expanding service offerings, funding acquisitions, repaying borrowings, and general corporate purposes. This strategic reallocation aims to enhance the company’s global expansion, diversify its services, and strengthen its market position.

Hangzhou Tigermed Proposes Amendments to Articles of Association

Hangzhou Tigermed Consulting Co., Ltd. announced proposed amendments to its Articles of Association, which were approved by its board of directors and will be submitted for shareholder approval at the 2024 annual general meeting. The amendments aim to expand the company’s business scope and align with relevant Chinese laws and stock exchange regulations, potentially impacting the company’s operational and regulatory framework.

Hangzhou Tigermed Declares Final Dividend for 2024

Hangzhou Tigermed Consulting Co., Ltd. has announced a final cash dividend of RMB 3 per 10 shares for the financial year ending December 31, 2024. The payment date for the dividend is set for July 31, 2025, with further details on shareholder approval and tax implications to be announced, indicating a stable financial performance and potential positive impact on shareholder value.

Hangzhou Tigermed Reports Significant Profit Decline in 2024

Hangzhou Tigermed Consulting Co., Ltd. announced its annual results for the year ended December 31, 2024, showing a significant decline in financial performance compared to the previous year. Revenue decreased by 10.6%, gross profit dropped by 21.3%, and net profit attributable to the owners fell by 80%. The company also reported a decrease in total assets and cash equivalents, with a proposed final dividend of RMB3.0 per 10 shares. These results indicate a challenging year for the company, impacting its profitability and financial stability.

Hangzhou Tigermed Consulting Schedules Board Meeting for Annual Results

Hangzhou Tigermed Consulting Co., Ltd. has announced that its Board of Directors will meet on March 27, 2025, to review and approve the company’s annual results for the year ending December 31, 2024. The meeting will also consider the recommendation for a final dividend payment, which could impact shareholder returns and reflect the company’s financial health.